CN111148535A - 治疗实体癌和血液癌的组合疗法 - Google Patents
治疗实体癌和血液癌的组合疗法 Download PDFInfo
- Publication number
- CN111148535A CN111148535A CN201880028490.2A CN201880028490A CN111148535A CN 111148535 A CN111148535 A CN 111148535A CN 201880028490 A CN201880028490 A CN 201880028490A CN 111148535 A CN111148535 A CN 111148535A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- cells
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 title abstract description 11
- 201000005787 hematologic cancer Diseases 0.000 title abstract description 7
- 238000002648 combination therapy Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 86
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 63
- 229940045799 anthracyclines and related substance Drugs 0.000 claims abstract description 24
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 22
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 14
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 13
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 13
- 229940100198 alkylating agent Drugs 0.000 claims abstract description 10
- 239000002168 alkylating agent Substances 0.000 claims abstract description 10
- 230000000340 anti-metabolite Effects 0.000 claims abstract description 9
- 229940100197 antimetabolite Drugs 0.000 claims abstract description 9
- 239000002256 antimetabolite Substances 0.000 claims abstract description 9
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims abstract description 9
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 8
- 239000003112 inhibitor Substances 0.000 claims abstract description 7
- 230000000394 mitotic effect Effects 0.000 claims abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 5
- 241000282414 Homo sapiens Species 0.000 claims description 525
- 210000004027 cell Anatomy 0.000 claims description 514
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 365
- 230000027455 binding Effects 0.000 claims description 321
- 210000004881 tumor cell Anatomy 0.000 claims description 200
- 239000000427 antigen Substances 0.000 claims description 178
- 102000036639 antigens Human genes 0.000 claims description 178
- 108091007433 antigens Proteins 0.000 claims description 178
- 239000012634 fragment Substances 0.000 claims description 166
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 130
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 110
- 206010028980 Neoplasm Diseases 0.000 claims description 103
- 230000030833 cell death Effects 0.000 claims description 79
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 73
- 210000002889 endothelial cell Anatomy 0.000 claims description 67
- 229960004679 doxorubicin Drugs 0.000 claims description 65
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 62
- 201000011510 cancer Diseases 0.000 claims description 58
- 210000003743 erythrocyte Anatomy 0.000 claims description 55
- 206010057249 Phagocytosis Diseases 0.000 claims description 47
- 230000008782 phagocytosis Effects 0.000 claims description 47
- 230000002829 reductive effect Effects 0.000 claims description 47
- 102000004082 Calreticulin Human genes 0.000 claims description 46
- 108090000549 Calreticulin Proteins 0.000 claims description 46
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 44
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 44
- 230000001965 increasing effect Effects 0.000 claims description 44
- 101150036449 SIRPA gene Proteins 0.000 claims description 42
- 102000044459 human CD47 Human genes 0.000 claims description 41
- 102000000412 Annexin Human genes 0.000 claims description 40
- 108050008874 Annexin Proteins 0.000 claims description 40
- 102100037907 High mobility group protein B1 Human genes 0.000 claims description 33
- 230000001225 therapeutic effect Effects 0.000 claims description 28
- 230000037449 immunogenic cell death Effects 0.000 claims description 27
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 25
- 101710113864 Heat shock protein 90 Proteins 0.000 claims description 25
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 25
- 230000004520 agglutination Effects 0.000 claims description 24
- 230000034994 death Effects 0.000 claims description 22
- 229960001156 mitoxantrone Drugs 0.000 claims description 22
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 22
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 21
- 230000001939 inductive effect Effects 0.000 claims description 21
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 19
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 18
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 17
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 17
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 17
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 17
- 101001098802 Homo sapiens Protein disulfide-isomerase A3 Proteins 0.000 claims description 16
- 102000002227 Interferon Type I Human genes 0.000 claims description 16
- 108010014726 Interferon Type I Proteins 0.000 claims description 16
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 claims description 16
- 230000002378 acidificating effect Effects 0.000 claims description 14
- 229960001756 oxaliplatin Drugs 0.000 claims description 14
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 14
- 229960004768 irinotecan Drugs 0.000 claims description 12
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 12
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 210000002919 epithelial cell Anatomy 0.000 claims description 11
- 229960005277 gemcitabine Drugs 0.000 claims description 11
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 11
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 10
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 10
- 229960001904 epirubicin Drugs 0.000 claims description 10
- 238000009097 single-agent therapy Methods 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 102000018697 Membrane Proteins Human genes 0.000 claims description 9
- 108010052285 Membrane Proteins Proteins 0.000 claims description 9
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 9
- 229960003668 docetaxel Drugs 0.000 claims description 9
- 210000005260 human cell Anatomy 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 claims description 7
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 claims description 7
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims description 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims description 7
- 210000002403 aortic endothelial cell Anatomy 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 108020003519 protein disulfide isomerase Proteins 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 6
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 6
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 229960000975 daunorubicin Drugs 0.000 claims description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 229960000908 idarubicin Drugs 0.000 claims description 6
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000000527 lymphocytic effect Effects 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 210000004926 tubular epithelial cell Anatomy 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 229940121849 Mitotic inhibitor Drugs 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 229960004964 temozolomide Drugs 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims description 2
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 108010021331 carfilzomib Proteins 0.000 claims description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 2
- 229960002438 carfilzomib Drugs 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
- 201000000052 gastrinoma Diseases 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 201000006894 monocytic leukemia Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 201000002511 pituitary cancer Diseases 0.000 claims description 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 206010042863 synovial sarcoma Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- 210000005239 tubule Anatomy 0.000 claims 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 36
- 238000011282 treatment Methods 0.000 abstract description 33
- 229940124597 therapeutic agent Drugs 0.000 abstract description 13
- 230000002265 prevention Effects 0.000 abstract description 5
- 229940127084 other anti-cancer agent Drugs 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 521
- 108090000672 Annexin A5 Proteins 0.000 description 118
- 102000004121 Annexin A5 Human genes 0.000 description 118
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 97
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 97
- 238000000684 flow cytometry Methods 0.000 description 91
- 239000012979 RPMI medium Substances 0.000 description 53
- 210000002540 macrophage Anatomy 0.000 description 46
- 150000001875 compounds Chemical class 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 37
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 230000000996 additive effect Effects 0.000 description 28
- 230000002195 synergetic effect Effects 0.000 description 28
- 241001529936 Murinae Species 0.000 description 27
- 239000000654 additive Substances 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 230000002860 competitive effect Effects 0.000 description 24
- 239000011159 matrix material Substances 0.000 description 24
- 230000003993 interaction Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 230000006870 function Effects 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 239000012636 effector Substances 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 210000004443 dendritic cell Anatomy 0.000 description 18
- 238000011534 incubation Methods 0.000 description 17
- 230000035931 haemagglutination Effects 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 14
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 239000013641 positive control Substances 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 238000002512 chemotherapy Methods 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 11
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 11
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000004602 germ cell Anatomy 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 210000001700 mitochondrial membrane Anatomy 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 102000013415 peroxidase activity proteins Human genes 0.000 description 10
- 108040007629 peroxidase activity proteins Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 239000004308 thiabendazole Substances 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102100036034 Thrombospondin-1 Human genes 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 9
- 230000000973 chemotherapeutic effect Effects 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 8
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 7
- 206010063837 Reperfusion injury Diseases 0.000 description 7
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000005975 antitumor immune response Effects 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000007876 drug discovery Methods 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 5
- 241000283074 Equus asinus Species 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 5
- 102000009109 Fc receptors Human genes 0.000 description 5
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 239000003560 cancer drug Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000004976 peripheral blood cell Anatomy 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 244000078127 Eleusine coracana Species 0.000 description 4
- 235000013499 Eleusine coracana subsp coracana Nutrition 0.000 description 4
- 244000182067 Fraxinus ornus Species 0.000 description 4
- 235000002917 Fraxinus ornus Nutrition 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 4
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000009509 drug development Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000007863 pattern recognition receptors Human genes 0.000 description 4
- 108010089193 pattern recognition receptors Proteins 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 235000002079 ragi Nutrition 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- -1 1-6 Proteins 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 231100000582 ATP assay Toxicity 0.000 description 3
- 241000271039 Agkistrodon Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 241000867607 Chlorocebus sabaeus Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000000849 HMGB Proteins Human genes 0.000 description 3
- 108010001860 HMGB Proteins Proteins 0.000 description 3
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 3
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 description 3
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 description 3
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 3
- 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000282695 Saimiri Species 0.000 description 3
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000002316 cosmetic surgery Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 101710108492 fMet-Leu-Phe receptor Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000027829 mitochondrial depolarization Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011885 synergistic combination Substances 0.000 description 3
- 101150060219 tsp-1 gene Proteins 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 102100034273 Annexin A7 Human genes 0.000 description 2
- 108010039940 Annexin A7 Proteins 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 description 2
- 101000986836 Homo sapiens P2Y purinoceptor 2 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 2
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 2
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010080192 Purinergic Receptors Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002546 agglutinic effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229940097217 cardiac glycoside Drugs 0.000 description 2
- 239000002368 cardiac glycoside Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 229930002534 steroid glycoside Natural products 0.000 description 2
- 150000008143 steroidal glycosides Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000004145 Annexin A1 Human genes 0.000 description 1
- 108090000663 Annexin A1 Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000207447 Estrella Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 206010056328 Hepatic ischaemia Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101710185235 High mobility group protein 1 Proteins 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000998950 Homo sapiens Immunoglobulin heavy variable 1-18 Proteins 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 101000998952 Homo sapiens Immunoglobulin heavy variable 1-3 Proteins 0.000 description 1
- 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 description 1
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 description 1
- 101000998951 Homo sapiens Immunoglobulin heavy variable 1-8 Proteins 0.000 description 1
- 101001037152 Homo sapiens Immunoglobulin heavy variable 2-26 Proteins 0.000 description 1
- 101001037145 Homo sapiens Immunoglobulin heavy variable 2-5 Proteins 0.000 description 1
- 101001037151 Homo sapiens Immunoglobulin heavy variable 2-70 Proteins 0.000 description 1
- 101001037138 Homo sapiens Immunoglobulin heavy variable 3-11 Proteins 0.000 description 1
- 101001037136 Homo sapiens Immunoglobulin heavy variable 3-15 Proteins 0.000 description 1
- 101001037142 Homo sapiens Immunoglobulin heavy variable 3-20 Proteins 0.000 description 1
- 101001037141 Homo sapiens Immunoglobulin heavy variable 3-21 Proteins 0.000 description 1
- 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 description 1
- 101001037139 Homo sapiens Immunoglobulin heavy variable 3-30 Proteins 0.000 description 1
- 101000839662 Homo sapiens Immunoglobulin heavy variable 3-48 Proteins 0.000 description 1
- 101000839658 Homo sapiens Immunoglobulin heavy variable 3-66 Proteins 0.000 description 1
- 101000839659 Homo sapiens Immunoglobulin heavy variable 3-72 Proteins 0.000 description 1
- 101000839687 Homo sapiens Immunoglobulin heavy variable 3-74 Proteins 0.000 description 1
- 101001037144 Homo sapiens Immunoglobulin heavy variable 3-9 Proteins 0.000 description 1
- 101000839684 Homo sapiens Immunoglobulin heavy variable 4-31 Proteins 0.000 description 1
- 101000839679 Homo sapiens Immunoglobulin heavy variable 4-39 Proteins 0.000 description 1
- 101000839781 Homo sapiens Immunoglobulin heavy variable 4-59 Proteins 0.000 description 1
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 description 1
- 101001138128 Homo sapiens Immunoglobulin kappa variable 1-12 Proteins 0.000 description 1
- 101001138126 Homo sapiens Immunoglobulin kappa variable 1-16 Proteins 0.000 description 1
- 101001138125 Homo sapiens Immunoglobulin kappa variable 1-17 Proteins 0.000 description 1
- 101001138123 Homo sapiens Immunoglobulin kappa variable 1-27 Proteins 0.000 description 1
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 description 1
- 101001138133 Homo sapiens Immunoglobulin kappa variable 1-5 Proteins 0.000 description 1
- 101001138130 Homo sapiens Immunoglobulin kappa variable 1-9 Proteins 0.000 description 1
- 101001008333 Homo sapiens Immunoglobulin kappa variable 1D-16 Proteins 0.000 description 1
- 101001008329 Homo sapiens Immunoglobulin kappa variable 1D-33 Proteins 0.000 description 1
- 101001008313 Homo sapiens Immunoglobulin kappa variable 1D-39 Proteins 0.000 description 1
- 101001047627 Homo sapiens Immunoglobulin kappa variable 2-28 Proteins 0.000 description 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 1
- 101001047629 Homo sapiens Immunoglobulin kappa variable 2-30 Proteins 0.000 description 1
- 101001008323 Homo sapiens Immunoglobulin kappa variable 2D-28 Proteins 0.000 description 1
- 101001008325 Homo sapiens Immunoglobulin kappa variable 2D-29 Proteins 0.000 description 1
- 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 description 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 1
- 101001008315 Homo sapiens Immunoglobulin kappa variable 3D-20 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 241000035030 Humata Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100036884 Immunoglobulin heavy variable 1-18 Human genes 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- 102100036886 Immunoglobulin heavy variable 1-3 Human genes 0.000 description 1
- 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 description 1
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 description 1
- 102100036885 Immunoglobulin heavy variable 1-8 Human genes 0.000 description 1
- 102100040230 Immunoglobulin heavy variable 2-26 Human genes 0.000 description 1
- 102100040235 Immunoglobulin heavy variable 2-5 Human genes 0.000 description 1
- 102100040233 Immunoglobulin heavy variable 2-70 Human genes 0.000 description 1
- 102100040222 Immunoglobulin heavy variable 3-11 Human genes 0.000 description 1
- 102100040224 Immunoglobulin heavy variable 3-15 Human genes 0.000 description 1
- 102100040218 Immunoglobulin heavy variable 3-20 Human genes 0.000 description 1
- 102100040217 Immunoglobulin heavy variable 3-21 Human genes 0.000 description 1
- 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 description 1
- 102100040219 Immunoglobulin heavy variable 3-30 Human genes 0.000 description 1
- 102100028320 Immunoglobulin heavy variable 3-48 Human genes 0.000 description 1
- 102100027821 Immunoglobulin heavy variable 3-66 Human genes 0.000 description 1
- 102100027820 Immunoglobulin heavy variable 3-72 Human genes 0.000 description 1
- 102100028305 Immunoglobulin heavy variable 3-74 Human genes 0.000 description 1
- 102100040234 Immunoglobulin heavy variable 3-9 Human genes 0.000 description 1
- 102100028310 Immunoglobulin heavy variable 4-31 Human genes 0.000 description 1
- 102100028312 Immunoglobulin heavy variable 4-39 Human genes 0.000 description 1
- 102100028405 Immunoglobulin heavy variable 4-59 Human genes 0.000 description 1
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 description 1
- 102100020773 Immunoglobulin kappa variable 1-12 Human genes 0.000 description 1
- 102100020946 Immunoglobulin kappa variable 1-16 Human genes 0.000 description 1
- 102100020945 Immunoglobulin kappa variable 1-17 Human genes 0.000 description 1
- 102100020902 Immunoglobulin kappa variable 1-27 Human genes 0.000 description 1
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 description 1
- 102100020769 Immunoglobulin kappa variable 1-5 Human genes 0.000 description 1
- 102100020770 Immunoglobulin kappa variable 1-9 Human genes 0.000 description 1
- 102100027462 Immunoglobulin kappa variable 1D-16 Human genes 0.000 description 1
- 102100027464 Immunoglobulin kappa variable 1D-33 Human genes 0.000 description 1
- 102100027404 Immunoglobulin kappa variable 1D-39 Human genes 0.000 description 1
- 102100022950 Immunoglobulin kappa variable 2-28 Human genes 0.000 description 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 1
- 102100022952 Immunoglobulin kappa variable 2-30 Human genes 0.000 description 1
- 102100027459 Immunoglobulin kappa variable 2D-28 Human genes 0.000 description 1
- 102100027458 Immunoglobulin kappa variable 2D-29 Human genes 0.000 description 1
- 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 description 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 1
- 102100027403 Immunoglobulin kappa variable 3D-20 Human genes 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101001047084 Mus musculus Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 1
- 102000012064 NLR Proteins Human genes 0.000 description 1
- 108091005686 NOD-like receptors Proteins 0.000 description 1
- 101710187081 OX-2 membrane glycoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000016227 Protein disulphide isomerases Human genes 0.000 description 1
- 108050004742 Protein disulphide isomerases Proteins 0.000 description 1
- 102000005583 Pyrin Human genes 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 241001338644 Retinia Species 0.000 description 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 230000006043 T cell recruitment Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000012635 anticancer drug combination Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000002886 autophagic effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000000443 biocontrol Effects 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 201000011281 bladder sarcoma Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 102000006783 calponin Human genes 0.000 description 1
- 108010086826 calponin Proteins 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000453 cell autonomous effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- VBCVPMMZEGZULK-NRFANRHFSA-N indoxacarb Chemical compound C([C@@]1(OC2)C(=O)OC)C3=CC(Cl)=CC=C3C1=NN2C(=O)N(C(=O)OC)C1=CC=C(OC(F)(F)F)C=C1 VBCVPMMZEGZULK-NRFANRHFSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000022006 malignant tumor of meninges Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 1
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000016914 response to endoplasmic reticulum stress Effects 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475032P | 2017-03-22 | 2017-03-22 | |
| US201762475036P | 2017-03-22 | 2017-03-22 | |
| US62/475,036 | 2017-03-22 | ||
| US62/475,032 | 2017-03-22 | ||
| US15/871,802 US20180142019A1 (en) | 2016-10-21 | 2018-01-15 | Therapeutic cd47 antibodies |
| US15/871,802 | 2018-01-15 | ||
| PCT/US2018/023860 WO2018175790A1 (en) | 2017-03-22 | 2018-03-22 | Combination therapy for the treatment of solid and hematological cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111148535A true CN111148535A (zh) | 2020-05-12 |
Family
ID=63585757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880028490.2A Pending CN111148535A (zh) | 2017-03-22 | 2018-03-22 | 治疗实体癌和血液癌的组合疗法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3600393A4 (enExample) |
| JP (1) | JP7170331B2 (enExample) |
| CN (1) | CN111148535A (enExample) |
| AU (1) | AU2018240377A1 (enExample) |
| CA (1) | CA3057139A1 (enExample) |
| SG (1) | SG11201908602UA (enExample) |
| WO (1) | WO2018175790A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| MX2015007446A (es) | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| BR112018005322A2 (pt) | 2015-09-18 | 2018-12-11 | Arch Oncology, Inc. | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| CN113166257B (zh) * | 2018-12-03 | 2023-05-30 | 上海开拓者生物医药有限公司 | Cd47抗体及其制备方法和应用 |
| JP2022532249A (ja) * | 2019-05-16 | 2022-07-13 | アーチ オンコロジー，インコーポレイテッド | インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法 |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| AU2020372327A1 (en) * | 2019-10-23 | 2022-06-02 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
| PE20230160A1 (es) | 2019-12-17 | 2023-02-01 | Pfizer | Anticuerpos especificos para cd47, pd-l1 y sus usos |
| CN114057876B (zh) * | 2020-07-31 | 2025-03-21 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101133083A (zh) * | 2003-11-11 | 2008-02-27 | 中外制药株式会社 | 人源化的抗cd47抗体 |
| CN104271757A (zh) * | 2012-02-06 | 2015-01-07 | 印希彼有限责任公司 | Cd47抗体及其使用方法 |
| US20160137733A1 (en) * | 2012-12-12 | 2016-05-19 | Vasculox Inc. | Therapeutic cd47 antibodies |
| WO2017049251A2 (en) * | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7696325B2 (en) * | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| PL2242773T3 (pl) * | 2008-02-11 | 2017-11-30 | Cure Tech Ltd. | Przeciwciała monoklonalne do leczenia nowotworu |
| US20110177064A1 (en) * | 2010-01-21 | 2011-07-21 | Immunogen, Inc. | Compositions and Methods for Treatment of Ovarian Cancer |
| SG10201704992SA (en) * | 2012-06-21 | 2017-07-28 | Compugen Ltd | Lsr antibodies, and uses thereof for treatment of cancer |
| KR102276974B1 (ko) * | 2013-02-06 | 2021-07-13 | 인히브릭스, 인크. | 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법 |
-
2018
- 2018-03-22 CN CN201880028490.2A patent/CN111148535A/zh active Pending
- 2018-03-22 JP JP2019551449A patent/JP7170331B2/ja active Active
- 2018-03-22 AU AU2018240377A patent/AU2018240377A1/en not_active Abandoned
- 2018-03-22 SG SG11201908602U patent/SG11201908602UA/en unknown
- 2018-03-22 EP EP18771103.1A patent/EP3600393A4/en not_active Withdrawn
- 2018-03-22 CA CA3057139A patent/CA3057139A1/en active Pending
- 2018-03-22 WO PCT/US2018/023860 patent/WO2018175790A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101133083A (zh) * | 2003-11-11 | 2008-02-27 | 中外制药株式会社 | 人源化的抗cd47抗体 |
| CN104271757A (zh) * | 2012-02-06 | 2015-01-07 | 印希彼有限责任公司 | Cd47抗体及其使用方法 |
| US20160137733A1 (en) * | 2012-12-12 | 2016-05-19 | Vasculox Inc. | Therapeutic cd47 antibodies |
| WO2017049251A2 (en) * | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
Non-Patent Citations (4)
| Title |
|---|
| JESSICA LO 等: "ANTI-CD47 ANTIBODY SUPPRESSES TUMOUR GROWTH AND AUGMENTS THE EFFECT OF CHEMOTHERAPY TREATMENT IN HEPATOCELLULAR CARCINOMA", 《LIVER INTERNATIONAL》 * |
| XIAOJUAN LIU 等: "CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors", 《NAT MED.》 * |
| 李黎等: "CD47与肿瘤免疫相关性研究进展 ", 《广东医学》 * |
| 鞠宝辉等: "抗CD47单克隆抗体对卵巢癌细胞靶向治疗的体外研究 ", 《中国肿瘤临床》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7170331B2 (ja) | 2022-11-14 |
| JP2020511481A (ja) | 2020-04-16 |
| AU2018240377A1 (en) | 2019-10-31 |
| EP3600393A1 (en) | 2020-02-05 |
| EP3600393A4 (en) | 2020-12-23 |
| SG11201908602UA (en) | 2019-10-30 |
| WO2018175790A1 (en) | 2018-09-27 |
| CA3057139A1 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11692035B2 (en) | Therapeutic CD47 antibodies | |
| US10844124B2 (en) | Therapeutic CD47 antibodies | |
| US11352424B2 (en) | Anti-Tim-3 antibodies for combination with anti-PD-1 antibodies | |
| CN111148535A (zh) | 治疗实体癌和血液癌的组合疗法 | |
| US20210324075A1 (en) | Therapeutic cd47 antibodies | |
| US20200024352A1 (en) | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies | |
| JP2022507295A (ja) | 治療用ＳＩＲＰα抗体 | |
| IL229254A (en) | Antibodies that bind c5ar and use them for treatment | |
| US20190309066A1 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| US20220313819A1 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| WO2020198370A2 (en) | Therapeutic cd47 antibodies | |
| WO2021263085A2 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| HK40031073A (en) | Combination therapy for the treatment of solid and hematological cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40031073 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200512 |
|
| WD01 | Invention patent application deemed withdrawn after publication |